HOX Therapeutics appoints Stephen Shuttleworth as non-executive director

Guildford, UK – 28th January 2019:  HOX Therapeutics, the private biotechnology company developing first-in-class, highly targeted cancer therapies based on HOX genes, announces the appointment of Dr Stephen Shuttleworth as Non-Executive Director.

Stephen is currently CSO and COO of Karus Therapeutics and is the founding scientist of the PI3K-p110β/δ and HDAC6 programs. He led the development of oral small molecule anti-tumour agents from concept to Phase I clinical trials. In January 2019, Stephen was also appointed Entrepreneur-in-Residence at Samsara BioCapital, California.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...